|Biotech Due Diligence||
Ligand partners will present numerous abstracts at the 2012 ASCO annual meeting in June. These include two phase 1 oncology drugs, CUDC-101 from Curis (see the abstract in my ASCO listing for $CRIS) and ME-143 from Marshall Edwards which were just recently revealed to utilize Captisol technology. Other data involves PROMACTA (eltrombopag) from $GSK, KYPROLIS (carfilzomib) from Onyx Pharma $ONXX, and SCH727965 from Merck $MRK. Expand the full post for all of the complete abstracts.
Curis will present several abstracts at the upcoming ASCO 2012 meeting in June related to ERIVEDGE (vismodegib), the hedgehog inhibitor being developed and commercialized by Roche/Genentech $RHHBY and one on CUDC-101, another cancer candidate. Expand the full post to read the complete abstract texts.
Astex Pharma $ASTX will have numerous presentations at ASCO 2012 in June. There will be two abstracts related to early clinical data for the AT13387 HSP90 inhibitor - I will cover these separately on the HSP90 Central blog. Phase 1 pediatric data for AT9283 and several abstracts related to DACOGEN (decitabine) will also be presented. Expand the full blog post for the complete text of each abstract.
Spectrum Pharma $SPPI will present data at the 2012 ASCO meeting in June on two cancer programs: belinostat and ZEVALIN. Expand the full post for the complete abstarcts.
Just when I think I can stop writing about BioSante Pharma $BPAX for awhile, the stock goes an pops 56% today with no apparent explanation. I'll run through a few of the spurious theories to explain the jump and discredit them.
EDIT: I decided to increase the number of theories from 4 to 8 due to inspiration from @AdamFeuerstein, @Gekkowire, and others. I'll address all eight - in reverse order of plausibility! Keep reading below for the full list.